1 / 4

Months since Randomization

RE-MEDY Cumulative Risk Recurrent Venous Thromboembolism or Related Death in the Active-Control Study. P=0.01 for noninferiority. Dabigatran. Estimated Cumulative Risk (%). Warfarin. Months since Randomization. Schulman S. N Engl J Med 2013;368:709-18.

vahe
Download Presentation

Months since Randomization

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RE-MEDYCumulative Risk Recurrent Venous Thromboembolism or Related Death in the Active-Control Study P=0.01 fornoninferiority Dabigatran EstimatedCumulative Risk (%) Warfarin MonthssinceRandomization Schulman S. N Engl J Med 2013;368:709-18.

  2. RE-SONATECumulative Risk Recurrent Venous Thromboembolism, Related Death, or Unexplained Death in the Placebo-Control Study Treatment Phase Post-Treatment Follow-up Matching placebo Dabigatran EstimatedCumulative Risk (%) P=0.01 at 6 mo P=0.006 at 12 mo P=0.03 at 18 mo MonthssinceRandomization Schulman S. N Engl J Med 2013;368:709-18.

  3. RE-MEDY Any Bleeding in the Active-Control Study Warfarin Dabigatran Estimated Cumulative Risk of Bleeding (%) P<0.001 Months since First Dose of Study Drug Schulman S. N Engl J Med 2013;368:709-18.

  4. RE-SONATEAny Bleeding in the Placebo-Control Study Dabigatran Matching placebo Estimated Cumulative Risk of Bleeding (%) P=0.003 Months since First Dose of Study Drug Schulman S. N Engl J Med 2013;368:709-18.

More Related